Company intelligence / Profile preview

Enveric Biosciences

Naples, Florida, USAenveric.com ↗
Ownership
Public · ENVB
Development stage
Other
01

Overview

EB-003 has demonstrated ability to bind to the 5-HT2A receptor and induce neuroplasticity without eliciting significant head twitch response in mice (a predictor of hallucinogenic effects in humans). The company is completing studies required for an IND application[6][8][9].

Therapeutic areas
Psychiatry
Modalities
Small moleculesneuroplastogenic compounds
Industry
Biotech
02

Drug pipeline

7 assets

EVM401

Preclinical

6 more assets in the full pipeline.

03

Partnerships

Restoration Biologics LLC (licensing agreement for joint disease treatment)[10]
04

Financials

Market cap
$6.3M
Total revenue
$0
Enterprise value
$-2M

Beyond the preview

Go deeper on Enveric Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enveric Biosciences.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call